Lusutrombopag: First Global Approval-Reference-Cited by-同舟云学术

Lusutrombopag: First Global Approval

Published:2015-12-14 Issue:1 Volume:76 Page:155-158
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Kim Esther S.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-015-0525-4.pdf

Reference16 articles.

1. Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48(6):1000–7.

2. Maan R, de Knegt RJ, Veldt BJ. Management of thrombocytopenia in chronic liver disease: focus on pharmacotherapeutic strategies. Drugs. 2015. doi: 10.1007/s40265-015-0480-0 .

3. Poordad F. Review article: thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther. 2007;26(Suppl 1):5–11.

4. European Medicines Agency. Revolade (eltrombopag) film-coated tablets. 2015. http://www.ema.europa.eu/ema/ . Accessed 1 Dec 2015.

5. US FDA. Promacta (eltrombopag) tablets: US prescribing information. 2015. http://www.fda.gov . Accessed 1 Dec 2015.

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thrombopoietin Receptor Agonists in Post-Hematopoietic Cell Transplantation Complicated by Prolonged Thrombocytopenia: A Comprehensive Review;ImmunoTargets and Therapy;2024-09

2. The role of the methoxy group in approved drugs;European Journal of Medicinal Chemistry;2024-07

3. A practical guide to the management of immune thrombocytopenia co-existing with acute coronary syndrome;Frontiers in Medicine;2024-04-11

4. Lusutrombopag as a Repurposing Drug in Combination with Aminoglycosides against Vancomycin-Resistant Enterococcus;ACS Infectious Diseases;2024-04-03

5. Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processing;Gastroenterología y Hepatología (English Edition);2024-03